


# Introduction and Scale-Up of New and Lesser-Used Postpartum Hemorrhage Medicines (NLUM-PPH) Catalytic Opportunity Fund (COF)

Milka Dinev | Reproductive Health Supplies Coalition

# About the COF

NLUM-PPH COF

This is a pool of funds, managed by the RHSC and CHAI and funded by MSD for Mothers\* and FCDO, is intended to increase access to new and lesser-used medicines for postpartum hemorrhage (NLUM-PPH) capable of preventing and treating PPH. This includes heat-stable carbetocin (HSC) for prevention of PPH and tranexamic acid (TXA) for the treatment of PPH. The goal is to provide funding for government-endorsed, catalytic preparatory activities that drive quality, new and lesser-used PPH medicines introduction and/or scale-up in low- and lower-middle-income countries.



\*MSD for Mothers is an initiative of Merck & Co., Inc., Rahway, NJ, USA.



## Catalytic Opportunities

Activities that enable increased efficiency and/or effectiveness of medicine introduction OR activities that are critical to achieve a successful medicine introduction.


Should demonstrate how they will lead to tangible, time-bound results for scale-up—specifically, leading to a sustainable increase in availability of quality NLU PPH medicines.

## Sustainability and Country Ownership

COF activities must be government-endorsed (e.g., relevant department involved in medicine introduction and/or maternal and neonatal child health).

Government should explicitly state there is adequate NLU PPH medicine stock or a procurement plan in place to ensure adequate stock to support activities.

COF activities should demonstrate how they utilize or build sustainable processes, systems, and/or resources for scale-up.



## Country Eligibility


- Low- or lower-middle-income countries.
- Included NLU PPH medicines into MOH Essential Medicines List and/or clinical guidelines.
- NLU PPH medicines have local regulatory approval or written commitment to pursue an importation waiver by the project start.
- Countries that have already made the decision to introduce the NLU PPH medicines.





## Medicine Eligibility

- Heat-stable carbetocin (HSC) for the prevention of PPH and tranexamic acid (TXA) for the treatment of PPH.
- Activities to scale HSC alone or with TXA are eligible. Activities to scale TXA alone are not eligible.



## Fund Parameters

- Implementing timeframes up to nine months.
- Funding ceiling of USD\$100,000 per application. However, there is no limit to the number of distinct applications that can be submitted per applicant.
- Applications are accepted on a rolling basis.